Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications.

Key topics discussed included:

The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency
The design and findings of the VERIFY study, highlighting the significant reduction in the need for phlebotomy among patients treated with rusfertide
The potential for individualized patient care and the integration of rusfertide with existing cytoreductive therapies
Insights into dosing, side effects, and the drug's impact on patient quality of life

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes!

#Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology

VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall

Oncology Brothers: Practice-Changing Cancer Discussions

VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall